Conference Coverage
Conference Coverage
Rituximab more effective than other MS treatments?
The risk for a first relapse was 6 times higher in patients receiving interferon beta or glatiramer acetate, compared with those receiving...
Conference Coverage
ECTRIMS/EAN statement on COVID-19 vaccination in patients with MS
The statement concludes that the COVID-19 vaccines that are currently available are safe for patients with MS.
Conference Coverage
The Barcelona baseline risk score may predict long-term MS course
30-year analysis supports MRI-heavy model that sorts patients into low-, medium-, and high-risk categories.
Conference Coverage
Ublituximab improves functional MS score: New ULTIMATE analysis
Trial data are being used to support a recent approval application to the FDA for ublituximab to treat patients with relapsing remitting MS.
Conference Coverage
In MS, baseline cortical lesions predict cognitive decline
Baseline MRI findings can inform cognitive monitoring over time.
Conference Coverage
Cortical lesions predict risk for secondary progressive MS
High numbers of cortical lesions at diagnosis are indicative of a more serious disease course.
Conference Coverage
Melatonin improves sleep in MS
A pilot clinical trials shows objective and subjective improvements.
Conference Coverage
COVID-19 vaccination in MS: Lower response on certain medications
Currently approved COVID-19 vaccines appear safe in patients with MS and are effective in most patients.
Conference Coverage
A less expensive, more convenient treatment option for MS?
If approved by the FDA, ublituximab would become the only glycoengineered anti-CD20 monoclonal antibody for MS.
Conference Coverage
Investigational drug reduces brain lesions in highly active MS
Tolebrutinib, a BTK inhibitor, reduced new gadolinium-enhancing lesions and new and enlarging T2 lesions.